COA Available
GLP-1 In Stock Research Use Only
Retatrutide
10mg · Lyophilized Powder · Purity ≥99%
Retatrutide is a long-acting synthetic peptide that simultaneously targets GLP-1, GIP, and glucagon receptors, studied in preclinical metabolic and energy homeostasis research models.
$139.99 CAD
Purchase Options
Subscriptions can be managed from your customer account. Prices in CAD.
Research Overview
Retatrutide is classified as a triagonist peptide due to its simultaneous activity at glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This multi-receptor profile distinguishes it from single- and dual-agonist compounds in the same research class and has made it a subject of interest in metabolic pathway research. This vial contains 10mg of Retatrutide supplied as a lyophilized powder with a documented purity of ≥99%, produced under quality-controlled conditions. Batch-level analytical documentation is accessible in the COA tab. This product is supplied exclusively for laboratory and in-vitro research applications — not for human or animal consumption.
Retatrutide belongs to a class of incretin-based peptides that have emerged as research tools in metabolic biology. Its triagonist mechanism — engaging GLP-1, GIP, and glucagon receptor pathways concurrently — places it in an area of active preclinical investigation examining energy regulation and metabolic signalling. Research on receptor polyagonism has expanded considerably in the metabolic sciences literature over the past decade. All research outcomes cited in scientific literature refer to preclinical and investigational settings and do not represent evidence of clinical safety or efficacy in humans.
Specifications
| Compound | Retatrutide |
| Format | Lyophilized Powder |
| Size | 10mg |
| Purity (HPLC) | ≥99% |
| Item # | BME-RETATR-A |
| Storage | −20°C, dry, dark |
| Price (CAD) | $139.99 |
COA / Testing
Batch documentation and third-party testing information are available for batch BME-RETATR-A. COA previews appear only when documentation exists for the active batch.
Storage & Handling
Store lyophilized Retatrutide powder at −20°C in a sealed, light-protected container. As with other peptides in this class, exposure to humidity or temperature fluctuations prior to use may affect compound stability. Avoid repeated freeze-thaw cycles. Once prepared for a research application, handle according to your laboratory's established protocols for synthetic peptide compounds. Consult current peer-reviewed resources for handling guidance specific to triagonist peptides.
Shipping & Returns
Orders are processed on business days. Packaging is selected to maintain compound integrity in transit. Shipping timelines and return conditions are outlined in full in the Shipping & Returns policy — review before checkout if you have specific requirements. For orders with time-sensitive research schedules, contact support before placing your order.
Research Use Disclaimer
This product is supplied strictly for in-vitro and laboratory research use. It is not a drug, food supplement, or cosmetic and is not approved for human or veterinary clinical applications, diagnostics, or therapeutic use. Researchers are responsible for compliance with all applicable institutional and regulatory requirements in their jurisdiction.
Preparation Reference Guide
Research Solution Reference Calculator
Pre-filled with 10mg. Enter your solvent volume and target amount to see concentration and units on a U-100 syringe scale.
Concentration—
Volume to draw—
Syringe units (U-100)—
Per insulin unit—
For research-use calculations only. Always verify measurements independently — not medical guidance.
Questions before you order?
Browse the FAQ for documentation, storage, and sourcing answers, or contact our support team directly. We aim to respond to all research procurement inquiries within one business day.
FAQ
Frequently Asked Questions
Retatrutide is a synthetic triagonist peptide that engages GLP-1, GIP, and glucagon receptors simultaneously, differentiating it from single- and dual-agonist compounds. This multi-receptor activity has made it a subject of interest in preclinical metabolic research. Supplied here for laboratory research use only.
Triple-agonist (triagonist) refers to a compound designed to activate three distinct receptor types — here: GLP-1, GIP, and glucagon receptors. Research interest in polyagonism centres on understanding how simultaneous multi-receptor engagement affects metabolic signalling pathways in preclinical models. This is a research classification, not a therapeutic descriptor.
Supplied at ≥99% purity, confirmed through batch-level analytical testing. A Certificate of Analysis is available in the COA tab for independent verification. Researchers are encouraged to review documentation prior to incorporation into any research protocol.
Yes. Batch-specific documentation including purity and identity testing data is available in the COA tab on this page. Documentation is updated per production batch and available for review prior to purchase.